A Systematic Review of Oral Semaglutide for Type II Diabetes

Abstract

Type 2 Diabetes mellitus is defined as metabolic disorder, for which the prevalence is getting very high close to a pandemic. Nearly more than three by fourth of the global population have type 2 Diabetes, making gestational diabetes and type 1 Diabetes (10%) with less incidence having symptoms like polydipsia, etc. It is diagnosed by Random, Post Prandial and Glycosylated Hemoglobin test. There are several class of medications like Alpha-Glycosidase Inhibitors, Biguanides & GLP-1 receptor agonists. Semaglutide is an agonist of glucagon-like-peptide 1 receptor. Formulation of Semaglutide into subcutaneous injection was successfully performed in the year of 2017 by Novo Nordisk, which was gloriously approved by the regulatory agencies. After two years from this incident, this drug was formulated and marketed in the form of tablet under the brand name "Rybellus". Semaglutide can also be considered as drug used in treatment of cardiovascular ailments like atherosclerosis other than anti-diabetic effect. Out of the oral GLP-1 agonizing agents, Semaglutide emerges to be one of the best drugs with anti-diabetic activity. The safety profile of oral Semaglutide is also looking greater in comparison with other members of the same class.